Recently, it has been reported that TLR2 agonists could be used directly (31–34) or as structurally modified forms (26) in cancer treatment, suggesting that TLR2 agonists can be potential effective enhancers for cancer immunotherapies. The gene discussed is TLR2; the disease is cancer.